Online registration for the Fall Convention is available now.
MAA Member $200.00
Non Member $250.00
Students (documentation req.) $30.00
We are pleased to announce our upcoming speakers for our 2017 convention, which takes place on Friday, October 13, 2017 at the Crowne Plaza Hotel in Natick, MA. We are grateful to Phonak as our 2017 Platinum sponsor! Thank you for your continued support of our local organization.
A BIG Thank You to our 2017 Platinum Sponsor--Phonak
Thank you to our 2017 Gold Sponsor
Thank you to our 2017 Silver Sponsors
Dr. H. Gustav Mueller is Professor of Audiology, Vanderbilt University, and he also holds faculty positions with the University of Northern Colorado and Rush University. He is the Senior Audiology consultant for Sivantos Group and Contributing Editor for AudiologyOnline. Dr. Mueller is a Founder of the American Academy of Audiology and a Fellow of the ASHA. He is the Hearing Aids Series Editor for Plural Publishing and has co-authored ten books. Gus is the founder of the popular web site www.earTunes.com, and has a private consulting practice nestled on a secluded western North Dakota island.
Hearing Aid Verification: Can you afford NOT to do it?
Research has shown the value of fitting patients to validated prescriptive algorithms. Other research has shown that this only can be accomplished by using probe-microphone measures (speechmapping). There is no Plan B. This seminar reviews the rationale for using validated prescriptive methods, and the serious mistakes that can be made when real-ear verification is not conducted. Through illustrative case studies, we’ll walk through some protocols to show how speechmapping measures can be used effectively (and efficiently) for verification of gain and output, and other tests for assessment of special hearing aid features.
Margaret A. Kenna, MD, MPH, is a graduate of the University of Pennsylvania (1974) and Boston University School of Medicine (1979). She completed her residency training in Otolaryngology-Head and Neck Surgery at the Univ. of Arkansas for Medical Sciences (1983) and fellowship in Pediatric Otolaryngology at the Children’s Hospital of Pittsburgh. Before coming to Boston, she was on the faculty at Children’s Hospital of Pittsburgh and Yale University School of Medicine.
Dr. Kenna has been on the Otolaryngology faculty at Boston Children’s Hospital since 1995. She co-founded the Children’s Hospital Boston Cochlear Implant Program, and was its Director from 1995-2003. Since 2003, she has been the Director of Clinical Research in the Dept. of Otolaryngology, Boston Children’s Hospital, and is Director of the Hearing Loss Program. She completed a Master’s in Public Health degree (MPH) in the area of Clinical Effectiveness at the Harvard School of Public Health in 2005.
Dr. Kenna’s early research concerned otitis media, especially chronic suppurative otitis media. Over the past 20 years she has focused on pediatric hearing loss, including genetic hearing loss, congenital CMV, and hearing loss secondary to ototoxicity in patients with Cystic Fibrosis. She is a long-standing member of the Universal Newborn Hearing Screening Advisory Committee of the MA Dept. of Public Health, and is a founding member of the Harvard Medical School Center for Hereditary Deafness.
Genetics Mini-Course: What does the Audiologist Need to Know?
Hearing loss is the most common congenital sensory impairment. Permanent bilateral severe to profound sensorineural HL (SNHL) is present in 1-2/1000 newborns, rising to 4/1000 including unilateral and milder bilateral SNHL. According to the National Health and Nutrition Examination Survey from 2001-2008, 20.3% of all subjects aged ≥12 years had permanent hearing loss. SNHL affects language, learning, social development, and employment success. The three major causes of newborn and childhood-onset hearing loss are infectious, anatomic, and genetic, with over 50% being genetic. Understanding the genetic mechanisms causing hearing loss is necessary to develop new therapies, and accurate baseline phenotype-genotype information is crucial against which to measure the safety and efficacy of any genetically–based therapies. Additionally, novel molecular therapies will require a precise genetic diagnosis, and may inform therapies for other aspects of syndromic SNHL. This course will explore the genetic basis of hearing loss, focusing on 1: common recessive hearing loss genes; 2. Common syndromic hearing loss genes; and 3. New genetic therapies to potentially treat hearing loss. Using a case-based format, the evaluation of genetic hearing loss as part of an overall diagnostic algorithm for congenital and childhood-onset hearing loss will be presented.
Elizabeth Thompson is the Director of Business Development for the VA and Audiology at Phonak US. She joined the Phonak team in 2008 and has served as the Northeast Government Territory Manager, Clinical Trainer and in various marketing roles including Product Manager. She received her MA in Audiology from Indiana University in 2002 and her AuD from Salus in 2008. Her previous work experience includes diagnostic audiometric evaluation, vestibular testing and rehabilitation, hearing instrument dispensing to pediatric through geriatric population, research with a focus on hearing instrument outcome measures and clinical supervision and teaching of AuD students at Indiana University.
Audiology Specialty Care clinics: Modern audiology, the old fashioned way
While the audiologist is often viewed as the specialist among the various channel options, there exists significant opportunity to elevate audiological care to a formal platform of specialty care clinics. Audiology Specialty Care Clinics will be defined by the level and scope of expert care for diagnosis and treatment, as well as impairment specific expertise.
Schedule of Events